Researchers from the University of Pennsylvania Medical Center and other institutions are starting to amass solid evidence to explain how a popular heart medication works on a molecular level. Specifically, the scientists investigated the role of cytokines (bodily proteins that regulate inflammation) in explaining the effectiveness of amlodipine, a widely prescribed calcium-channel blocker for patients with heart failure. "A better understanding of the relationship between cytokines and amlodipine will hopefully open the door to develop more effective therapies for congestive heart failure, a condition that affects about three million Americans," says Emile R. Mohler, III, MD, director of vascular medicine at Penn. Mohler presents his findings today at the European Congress of Cardiology in Stockholm Sweden.
The above story is based on materials provided by University Of Pennsylvania Medical Center. Note: Materials may be edited for content and length.
Cite This Page: